Henri van Luenen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Henri van Luenen has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Aaike van Oord
Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
1 shared publication - Abinaya Rajan
Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
1 shared publication - Annegien Broeks
Core Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute, Amsterdam, the Netherlands
1 shared publication - Carlos Caldas
Department of Clinical Biochemistry and Institute of Metabolic Science, School of Clinical Medicine, University of Cambridge, Cambridge, UK
1 shared publication - Irith Kist
Board of Directors Administration and Legal Department, The Netherlands Cancer Institute, Amsterdam, The Netherlands
1 shared publication - Mahasti Saghatchian
Institut Gustave Roussy, Villejuif 94805, France
1 shared publication
Latest Publications
- Open Access
- 9 January 2026
- Published by Springer Nature in BMC Medical Ethics
- Vol. 27 (1)
Implementing broad consent for research with routinely collected clinical data and residual biosamples in a cancer hospital: using mixed methods approach to evaluate consent rates and patients’ perspectives
Patients are generally willing to contribute to research with routinely collected health data and residual biosamples, but transparency and being able to (
- 9 January 2026
- Published by Springer Nature in BMC Medical Ethics
- Vol. 27 (1)
Open AccessImplementing broad consent for research with routinely collected clinical data and residual biosamples in a cancer hospital: using mixed methods approach to evaluate consent rates and patients’ perspectives
Patients are generally willing to contribute to research with routinely collected health data and residual biosamples, but transparency and being able to (
- Open Access
- 29 October 2013
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 11 (1) , 274
Assessing excellence in translational cancer research: a consensus based framework
It takes several years on average to translate basic research findings into clinical research and eventually deliver patient benefits. An expert-based excellence assessment can help improve this process by: identifying high performing Comprehensive Cancer Centres; best practices in translational cancer research; improving the quality and efficiency of the translational cancer research process. This can help build networks of excellent Centres by aiding focused partnerships. In this paper we report on a consensus building exercise that was undertaken to construct an excellence assessment framework for translational cancer research in Europe.
- 29 October 2013
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 11 (1) , 274
Open AccessAssessing excellence in translational cancer research: a consensus based framework
It takes several years on average to translate basic research findings into clinical research and eventually deliver patient benefits. An expert-based excellence assessment can help improve this process by: identifying high performing Comprehensive Cancer Centres; best practices in translational cancer research; improving the quality and efficiency of the translational cancer research process. This can help build networks of excellent Centres by aiding focused partnerships. In this paper we report on a consensus building exercise that was undertaken to construct an excellence assessment framework for translational cancer research in Europe.